Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2020

View Archived Issues

Grant supports Epsilogen's development of cancer immunotherapeutic EPS-201

Targeting periphery could be viable approach in ALS

Ideaya and the Broad Institute partner to advance synthetic lethality programs

GlaxoSmithKline patents hSTING agonists

Kowa discloses CSF-1R inhibitors

TaiwanJ Pharmaceuticals presents new ENPP2 and HDAC dual inhibitors

Tera Stone synthesizes new compounds for cancer

Researchers discover new CNKs as antitumoral agents

FDA clears IND application for first-in-human study of ADI-001

Ionis initiates phase I/II study of ION-541 to treat broad ALS population

First-in-human data presented for JAK3 inhibitor TD-5202

Lp-PLA2 inhibition may limit cardiovascular damage from radiotherapy

FDA approves Veklury for patients with COVID-19 requiring hospitalization

Galera initiates phase I/II GRECO-1 study of GC-4711 plus SBRT in NSCLC

FDA issues complete response letter for Qtrypta

Preclinical data presented on intranasal oxytocin formulation for IBS

SGX-301 continues to demonstrate positive benefits in phase III FLASH study

ProTrans approved for clinical trials in patients with COVID-19

New phase II trial investigates PT-112 for metastatic CRPC

SARS-CoV-2 vaccine BBIBP-CorV safe and induces humoral responses in phase I/II study

bit.bio and London Institute for Mathematical Sciences partner on production of human cells

Adalimumab s.c. efficacious and safe option for children with ulcerative colitis

Altered cathepsin K secretion contributes to congenital heart defects in a model of mucolipidosis II

Phase III studies of a quadrivalent virus-like particle influenza vaccine manufactured in plants

AstraZeneca initiates phase III trial of monalizumab in recurrent or metastatic SCCHN

Tetra reports findings with ARDS-003 in induced pulmonary fibrosis model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...